"We are pleased to offer Myqorzo and Redemplo to patients in Greater China. These two medicines represent significant advances in treatment options and address unmet medical needs for people living with complex conditions," said Olivier Charmeil, Executive Vice President, General Medicines at Sanofi, in a statement.
Myqorzo (aficamten) helps treat obstructive hypertrophic cardiomyopathy (oHCM), while Redemplo (plozasiran) is intended for patients with familial chylomicronemia syndrome (FCS), a severe and rare disease, according to Sanofi's statement.
(Written by Mara Vîlcu, edited by Augustin Turpin)
